Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

September 01, 2012; Volume 40,Issue 9

Commentary

  • You have access
    Commentary: Nonspecific Protein Binding versus Membrane Partitioning: It Is Not Just Semantics
    Swati Nagar and Ken Korzekwa
    Drug Metabolism and Disposition September 2012, 40 (9) 1649-1652; DOI: https://doi.org/10.1124/dmd.112.046599

Short Communication

  • You have access
    Risk Assessment of Mechanism-Based Inactivation in Drug-Drug Interactions
    Yasushi Fujioka, Kent L. Kunze and Nina Isoherranen
    Drug Metabolism and Disposition September 2012, 40 (9) 1653-1657; DOI: https://doi.org/10.1124/dmd.112.046649

Articles

  • You have access
    Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4
    Howard J. Burt, Henry Pertinez, Carolina Säll, Claire Collins, Ruth Hyland, J. Brian Houston and Aleksandra Galetin
    Drug Metabolism and Disposition September 2012, 40 (9) 1658-1667; DOI: https://doi.org/10.1124/dmd.112.046078
  • You have access
    A Novel Ring Oxidation of 4- or 5-Substituted 2H-Oxazole to Corresponding 2-Oxazolone Catalyzed by Cytosolic Aldehyde Oxidase
    Vinod K. Arora, Thomas Philip, Stella Huang and Yue-Zhong Shu
    Drug Metabolism and Disposition September 2012, 40 (9) 1668-1676; DOI: https://doi.org/10.1124/dmd.112.044545
  • You have access
    Development of a Carbon-14 Labeling Approach to Support Disposition Studies with a Pegylated Biologic
    Haiqing Wang, Lifei Wang, Kai Cao, Stuart L. Emanuel, Paul Morin, Zheng Lin, Guoxiang Shen, Jennifer Hosbach, Donglu Zhang, Samuel Bonacorsi, A. David Rodrigues and Zheng Yang
    Drug Metabolism and Disposition September 2012, 40 (9) 1677-1685; DOI: https://doi.org/10.1124/dmd.112.044792
  • You have access
    Selective Mechanism-Based Inactivation of CYP3A4 by CYP3cide (PF-04981517) and Its Utility as an In Vitro Tool for Delineating the Relative Roles of CYP3A4 versus CYP3A5 in the Metabolism of Drugs
    Robert L. Walsky, R. Scott Obach, Ruth Hyland, Ping Kang, Sue Zhou, Michael West, Kieran F. Geoghegan, Christopher J. Helal, Gregory S. Walker, Theunis C. Goosen and Michael A. Zientek
    Drug Metabolism and Disposition September 2012, 40 (9) 1686-1697; DOI: https://doi.org/10.1124/dmd.112.045302
  • You have access
    Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19
    Tatyana Zvyaga, Shu-Ying Chang, Cliff Chen, Zheng Yang, Ragini Vuppugalla, Jeremy Hurley, Denise Thorndike, Andrew Wagner, Anjaneya Chimalakonda and A. David Rodrigues
    Drug Metabolism and Disposition September 2012, 40 (9) 1698-1711; DOI: https://doi.org/10.1124/dmd.112.045575
  • You have access
    Metabolism and Pharmacokinetics of Indacaterol in Humans
    Mark Kagan, Jeremy Dain, Lana Peng and Christine Reynolds
    Drug Metabolism and Disposition September 2012, 40 (9) 1712-1722; DOI: https://doi.org/10.1124/dmd.112.046151
  • You have access
    Excretion and Metabolism of Milnacipran in Humans after Oral Administration of Milnacipran Hydrochloride
    Fanying Li, Christina Chin, Julie Wangsa and John Ho
    Drug Metabolism and Disposition September 2012, 40 (9) 1723-1735; DOI: https://doi.org/10.1124/dmd.112.045120
  • You have access
    Role of Human UDP-Glucuronosyltransferases in the Biotransformation of the Triazoloacridinone and Imidazoacridinone Antitumor Agents C-1305 and C-1311: Highly Selective Substrates for UGT1A10
    Barbara Fedejko-Kap, Stacie M. Bratton, Moshe Finel, Anna Radominska-Pandya and Zofia Mazerska
    Drug Metabolism and Disposition September 2012, 40 (9) 1736-1743; DOI: https://doi.org/10.1124/dmd.112.045401
  • You have access
    Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes
    Karelle Ménochet, Kathryn E. Kenworthy, J. Brian Houston and Aleksandra Galetin
    Drug Metabolism and Disposition September 2012, 40 (9) 1744-1756; DOI: https://doi.org/10.1124/dmd.112.046193
  • You have access
    Evaluation of P450 Inhibition and Induction by Artemisinin Antimalarials in Human Liver Microsomes and Primary Human Hepatocytes
    Jie Xing, Brian J. Kirby, Dale Whittington, Yakun Wan and David R. Goodlett
    Drug Metabolism and Disposition September 2012, 40 (9) 1757-1764; DOI: https://doi.org/10.1124/dmd.112.045765
  • You have access
    Mechanism-Based Inactivation of Cytochrome P450 2B6 by Methadone through Destruction of Prosthetic Heme
    Hemali T. Amunugama, Haoming Zhang and Paul F. Hollenberg
    Drug Metabolism and Disposition September 2012, 40 (9) 1765-1770; DOI: https://doi.org/10.1124/dmd.112.045971
  • You have access
    Quantitative Prediction of Human Intestinal Glucuronidation Effects on Intestinal Availability of UDP-Glucuronosyltransferase Substrates Using In Vitro Data
    Fumihiro Nakamori, Yoichi Naritomi, Ken-ichi Hosoya, Hiroyuki Moriguchi, Kazuhiro Tetsuka, Takako Furukawa, Keitaro Kadono, Katsuhiro Yamano, Shigeyuki Terashita and Toshio Teramura
    Drug Metabolism and Disposition September 2012, 40 (9) 1771-1777; DOI: https://doi.org/10.1124/dmd.112.045476
  • You have access
    Metabolism of the Active Metabolite of Quetiapine, N-Desalkylquetiapine In Vitro
    Gry Vibeke Bakken, Espen Molden, Karoline Knutsen, Niclas Lunder and Monica Hermann
    Drug Metabolism and Disposition September 2012, 40 (9) 1778-1784; DOI: https://doi.org/10.1124/dmd.112.045237
  • You have access
    Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human
    Laurent Salphati, Jodie Pang, Emile G. Plise, Leslie B. Lee, Alan G. Olivero, Wei Wei Prior, Deepak Sampath, Susan Wong and Xiaolin Zhang
    Drug Metabolism and Disposition September 2012, 40 (9) 1785-1796; DOI: https://doi.org/10.1124/dmd.112.046052
  • You have access
    Evaluation of Inhibition Selectivity for Human Cytochrome P450 2A Enzymes
    Eva S. Stephens, Agnes A. Walsh and Emily E. Scott
    Drug Metabolism and Disposition September 2012, 40 (9) 1797-1802; DOI: https://doi.org/10.1124/dmd.112.045161
  • You have access
    Discovery of a Highly Selective CYP3A4 Inhibitor Suitable for Reaction Phenotyping Studies and Differentiation of CYP3A4 and CYP3A5
    Xiaohai Li, Xinyi Song, Theodore M. Kamenecka and Michael D. Cameron
    Drug Metabolism and Disposition September 2012, 40 (9) 1803-1809; DOI: https://doi.org/10.1124/dmd.112.046144
  • You have access
    Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent
    Jan Scicinski, Bryan Oronsky, Michael Taylor, Gang Luo, Timothy Musick, Joseph Marini, Christopher M. Adams and William L. Fitch
    Drug Metabolism and Disposition September 2012, 40 (9) 1810-1816; DOI: https://doi.org/10.1124/dmd.112.046755
  • You have access
    Altered Arsenic Disposition in Experimental Nonalcoholic Fatty Liver Disease
    Mark J. Canet, Rhiannon N. Hardwick, April D. Lake, Michael J. Kopplin, George L. Scheffer, Walter T. Klimecki, A. Jay Gandolfi and Nathan J. Cherrington
    Drug Metabolism and Disposition September 2012, 40 (9) 1817-1824; DOI: https://doi.org/10.1124/dmd.112.046177
  • You have access
    Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics
    Maciej J. Zamek-Gliszczynski, David W. Bedwell, Jing Q. Bao and J. William Higgins
    Drug Metabolism and Disposition September 2012, 40 (9) 1825-1833; DOI: https://doi.org/10.1124/dmd.112.046508
  • You have access
    The Role of Aldehyde Oxidase and Xanthine Oxidase in the Biotransformation of a Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5
    Ryan D. Morrison, Anna L. Blobaum, Frank W. Byers, Tammy S. Santomango, Thomas M. Bridges, Donald Stec, Katrina A. Brewer, Raymundo Sanchez-Ponce, Melany M. Corlew, Roger Rush, Andrew S. Felts, Jason Manka, Brittney S. Bates, Daryl F. Venable, Alice L. Rodriguez, Carrie K. Jones, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte and J. Scott Daniels
    Drug Metabolism and Disposition September 2012, 40 (9) 1834-1845; DOI: https://doi.org/10.1124/dmd.112.046136
  • You have access
    Influence of Enterohepatic Recycling on the Time Course of Brain-to-Blood Partitioning of Valproic Acid in Rats
    Jeannie M. Padowski and Gary M. Pollack
    Drug Metabolism and Disposition September 2012, 40 (9) 1846-1853; DOI: https://doi.org/10.1124/dmd.112.045500
  • You have access
    Glutaredoxin Is Involved in the Formation of the Pharmacologically Active Metabolite of Clopidogrel from Its GSH Conjugate
    Katsunobu Hagihara, Miho Kazui, Atsushi Kurihara, Toshihiko Ikeda and Takashi Izumi
    Drug Metabolism and Disposition September 2012, 40 (9) 1854-1859; DOI: https://doi.org/10.1124/dmd.112.045914

Accelerated Communication

  • You have access
    A Novel Relay Method for Determining Low-Clearance Values
    Li Di, Patrick Trapa, R. Scott Obach, Karen Atkinson, Yi-An Bi, Angela C. Wolford, Beijing Tan, Thomas S. McDonald, Yurong Lai and Larry M. Tremaine
    Drug Metabolism and Disposition September 2012, 40 (9) 1860-1865; DOI: https://doi.org/10.1124/dmd.112.046425

Errata

  • You have access
    Correction to “Identification of Novel Metoclopramide Metabolites in Humans: In Vitro and In Vivo Studies”
    Drug Metabolism and Disposition September 2012, 40 (9) 1866; DOI: https://doi.org/10.1124/dmd.40.9.1866
  • You have access
    Correction to “Identification and Validation of Novel Human Pregnane X Receptor Activators among Prescribed Drugs via Ligand-Based Virtual Screening”
    Drug Metabolism and Disposition September 2012, 40 (9) 1868; DOI: https://doi.org/10.1124/dmd.40.9.1868
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition: 40 (9)
Drug Metabolism and Disposition
Vol. 40, Issue 9
1 Sep 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • Commentary
  • Short Communication
  • Articles
  • Accelerated Communication
  • Errata
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics